research Methimazole, Carbimazole, And Congenital Skin Defects
The document discussed the potential risks associated with the use of methimazole and carbimazole, antithyroid drugs, during pregnancy. It highlighted concerns about congenital skin defects, specifically aplasia cutis, which were reported in some cases where mothers took methimazole while pregnant. The document referenced studies from the early 1970s that observed congenital scalp defects in 12 patients, with methimazole exposure noted in 3 cases, including a pair of fraternal twins. These findings led to recommendations against the use of methimazole in pregnant women with hyperthyroidism due to the potential teratogenic effects.